A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Barry J. Snow; Fiona L. Rolfe; Michelle M. Lockhart; Christopher M. Frampton; John D. O'Sullivan; Victor Fung; Robin A.J. Smith; Michael P. Murphy; Kenneth M. Taylor; Protect Study Grp

doi:10.1002/mds.23148

Back

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Journal article

Peer reviewed

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Barry J. Snow, Fiona L. Rolfe, Michelle M. Lockhart, Christopher M. Frampton, John D. O'Sullivan, Victor Fung, Robin A.J. Smith, Michael P. Murphy, Kenneth M. Taylor and Protect Study Grp

Movement disorders, Vol.25(11), pp.1670-1674

15/08/2010

DOI: https://doi.org/10.1002/mds.23148

Handle:

https://hdl.handle.net/10523/33087

Abstract

mitochondria

MitoQ

neuroprotection

oxidative damage

Metrics

17 Record Views

465 Times Cited - Web of Science

See more details

Details

Record Identifier: 9926517933901891
Title: A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
Creators: Barry J. Snow
Fiona L. Rolfe
Michelle M. Lockhart
Christopher M. Frampton
John D. O'Sullivan
Victor Fung
Robin A.J. Smith
Michael P. Murphy
Kenneth M. Taylor
Protect Study Grp
Publication Details: Movement disorders, Vol.25(11), pp.1670-1674
Academic Unit: Medicine (UOC)
Publisher: Wiley Subscription Services, Inc., A Wiley Company
Date published ; e-published: 15/08/2010
Language: English
Resource Type ; Subtype: Journal article

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Abstract

Related links

Metrics

Details